According to Higgs, treatment with the drug is well tolerated, suggesting that it holds some guarantees as an Ebola treatment.
Dr. Higgs made the statement recently at the Ministry of Information Culture and Tourism (MICAT) press briefing in Monrovia.
ZMapp, which was made by Mapp Biopharmaceuticals Inc. in California USA, is a mixture of three different anti-Ebola antibodies.
She said antibodies are infection-fighting proteins produced by the body which are attached to the surface of the Ebola virus, and thereby prevent it from damaging the cell.
According to Higgs, the randomized controlled study was designed to enroll up to 200 patients of any age with confirmed Ebola virus infection.
She said during 10 months of the study, which began on March 13, 2015 some 72 patients were enrolled, and on January 29, 2016 the trial leaders closed the study because no more cases were expected.
The 72 participants included 54 from seven clinical sites in Sierra Leone, 12 from Guinea, 5 from two sites in Liberia, and 1 from the United States, she added.
“To assess how well ZMapp works against Ebola, the PREVAIL team compared the number of deaths in each group at 28 days after enrollment.
In the study, 21 patients died at a mortality rate of almost 30 percent, while the standard-of-care group had 13/35/ (37) percent deaths compared with 8/36 (22 percent) deaths in the ZMapp group, Dr. Higgs said.
In February 2015, the PREVAIL launched an Ebola vaccine trial in Liberia as their first study, but it was criticized by the public due to lack of sufficient information on the ZMapp vaccine.
PREAVIL one and PREVAIL two tested an experimental Ebola treatment known as ZMapp in patients enrolled in West Africa and the United States.